Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison-Reference-Cited by-同舟云学术

Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison

Published:2023-05 Issue: Volume:179 Page:107186
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ou Sai-Hong I.,Lin Huamao M.,Hong Jin-Liern,Yin Yu,Jin Shu,Lin Jianchang,Mehta Minal,Zhang Pingkuan,Nguyen Danny,Neal Joel W.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference54 articles.

1. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII);Midha;Am. J. Cancer Res.,2015

2. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang;Oncotarget.,2016

3. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions;Oxnard;J Thorac Oncol.,2013

4. Diverse EGFR exon 20 insertions and co-occurring molecular alteration identified by comprehensive genomic profiling in NSCLC;Riess;J Thorac Oncol.,2018

5. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer;Fang;BMC Cancer.,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;CLIN LUNG CANCER;2024

2. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;Clinical Lung Cancer;2024-09